Chemomab Therapeutics (CMMB) - Net earnings per share (EPS TTM)

Symbol and logo of brand Chemomab Therapeutics Ltd. (CMMB)

Chemomab Therapeutics (CMMB), an Israeli developer of inflammatory liver disease therapies, is demonstrating steady research progress. Net profit per share dynamics confirm the current trajectory, where -1.01 shows the value of this parameter. Risks are being minimized through the diversification of antibody clinical trial stages and the engagement of external CROs to ensure the efficient execution of medical trials without supply chain disruptions.

CMMB (chemomab.com) Earnings per share for the last 12 months history from 07/04/2022 to 11/16/2026

Comprehensive metric breakdowns and analytics for Chemomab (CMMB)

General company analysis:Chemomab Therapeutics Ltd. (CMMB)
Mass-produced product of Chemomab Therapeutics Ltd

Chemomab Therapeutics (CMMB) specializes in developing innovative drugs for the treatment of rare fibro-inflammatory pathologies. This indicator measures the portion of net income attributable to a single common share over a rolling year. Such a metric allows investors to assess the actual efficiency of business capitalization without accounting for quarterly fluctuations. Amid high demand for orphan drugs, this figure reflects the company's ability to convert research and development into revenue. By analyzing the trend of annual net income per share, one can identify the risk of margin compression or confirm fundamental growth.

Competitors of Chemomab Therapeutics (CMMB)

VRTX: Net earnings per share for the last 12 months|Earnings per one share for the last 12 months ALNY|INSM: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months United Therapeutics Corp. (UTHR)|BMRN (BioMarin) - Net earnings per share (EPS TTM)|Earnings per share for the last 12 months BBIO (BridgeBio)|Earnings per share for the last twelve months bgm.ltd (BGM)|COGT (Cogent Biosciences Inc) - Earnings per share for the trailing year|Earnings per share for the last twelve months Xeris Biopharma Holdings XERS|KROS (Keros Pharma) - Earnings per one share for the last 12 months|Arcturus Therapeutics - Net earnings per share (EPS TTM)|Earnings per share for the trailing year ETON (Eton Pharmaceuticals)|KMDA: Net earnings per share (EPS TTM)|Fulcrum Therapeutics Inc (FULC) - Net earnings per share (EPS TTM)|Earnings per share for the last twelve months abeonatherapeutics.com|MREO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) PLX|Net earnings per share for the last 12 months Pliant Therapeutics, Inc. PLRX|Net earnings per share (EPS TTM) APLT (Applied Therapeutics Inc.)|Net earnings per share (EPS TTM) Rein Therapeutics Inc. RNTX|gelteq.com - Net earnings per share (EPS TTM)|AYTU - Net earnings per share (EPS TTM)|SRx Health (SRXH) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months Polyrizon Ltd. (PLRZ)|Net earnings per share for the last 12 months AEZS|Net earnings per share for the last 12 months Cyclo Therapeutics Inc. (CYTH)|Net earnings per share for the last 12 months INZY (inozyme.com)|RPHM - Net earnings per one share for the last twelve months|Net earnings per share (EPS TTM) CSCI (cosciensbio.com)